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Abstract 
Background: Metastatic colorectal cancer is 
an incurable illness; however the advent of 
chemotherapy has significantly improved survival 
and symptom control. FOLFOX and FOLFIRI are 
used at SPBOH as the standard of care for patients 
with metastatic disease. No statistical data is 
available on that cohort of patients; this study aims 
to establish a population data-set for patients on 
FOLFOX/FOLFIRI.   
Methods: This retrospective cross-sectional 
study included all patients on FOLFOX and 
FOLFIRI in 2014. Only male patients were 
included, data was retrospectively extracted from 
the ward’s logbook and ISOFT clinical manager. 
Cycle 1, 6 and 12 dates were documented. Data was 
analysed using clinically reliable statistical tools, all 
reported p-values were statistically significant at 
<0.05. 
Results: From a total of 108 patients, 4 
patients were excluded from the analysis. The 
average age of patients was 65.2 years. The average 
length of 12 cycles was 24.5 weeks. 19% of patients 
had cycles longer than 7 months whereas only 10% 
lasted more than 8 months on treatment. 41% of 
patients dropped out before completing the full 
course with a complication and mortality rate of 
17%. Patients on FOLFIRI were more likely to 
have their chemotherapy changed and were also 
more likely to have received previous treatment.  
Conclusion: Although chemotherapy increases 
survival in metastatic colorectal cancer we have to 
appreciate that many patients do not proceed 
smoothly with their treatment. Many of those 
patients are middle aged independent individuals, 
after-all the physician must draw the line at the 
appropriate time and focus on palliative care rather 
than continuing ineffectively with chemotherapy.  
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Introduction 
With a global incidence of 1.2 million cases 
annually, colorectal cancer stands as one of the 
most common and lethal malignancies. It is the 
fourth most common cause of death in men and the 
third in women, killing an estimate of 608,700 
patients each year.1 In the developed world, death 
rate from colorectal cancer has been decreasing, 
mainly due to screening and the detection and 
treatment of early stage disease. Population based 
screening programmes are usually not affordable in 
many parts of the world because of the expense of 
colonoscopy.2 Loco-regional data is lacking, 
however in the United States, around 2/5 of 
colorectal cancer patients present with stage I and II 
local disease, around 2/5 with regionally advanced 
stage III disease and 1/5 with metastases.3 
Metastatic colorectal cancer is an incurable 
illness, however in the advent of chemotherapy 
survival and symptom relief has significantly 
improved. Chemotherapy for metastatic colorectal 
cancer has developed in a stepwise fashion over the 
past decades. 5-FU was the first chemotherapeutic 
agent shown to be effective. Subsequently the 
regimen of 5- FU/cisplatin/folinic acid, was shown 
to increase survival in metastatic colorectal cancer 
from 5 to 11 months.4 More so two cytotoxic 
chemotherapies exhibited considerable efficacy 
when added to the 5-FU/folinic acid backbone. It is 
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combined with Oxaliplatin in the FOLFOX 
infusional regimen and with Irinotecan in the 
FOLFIRI regimen.  Multiple clinical trials have 
shown that the FOLFIRI and FOLFOX regimens 
are equivalent in terms of efficacy. For first line 
therapy, oncologists typically choose between 
FOLFOX and FOLFIRI based on the side effect 
profile of both regimens.5-6  
To prolong survival and improve quality of 
life, palliative chemotherapy is administered to 
patients with locally advanced or metastatic cancer. 
As a result of this established benefit, the 1990 
National Institutes of Health Consensus Panel on 
Colorectal Cancer recommended routine 5-FU-
based adjuvant chemotherapy for patients with 
node-positive (stage-III) colon cancer. This was 
originally recommended for 12 months, and later on 
revised to 6 months because of proven equivalence 
in survival benefits. 7- 9 
As the only provider of systemic 
chemotherapy treatment in Malta, Sir Paul Boffa 
Oncology Hospital (SPBOH) serves the whole 
population of Malta and Gozo and caters for a wide 
array of cancer patients.  FOLFOX and FOLFIRI 
are used at SPBOH as the standard of care for 
patients with metastatic as well as adjuvant 
colorectal cancer treatment. It is important to note 
that the initiation of adjuvant/palliative 
chemotherapy is just the first step in survival 
improvement. Because the completion of 
chemotherapy is associated with increased survival, 
it is essential to complete the chemotherapy cycles 
once initiated.7 Little is known about the actual 
completion rate of such a therapy in our 
community, and we were unable to identify other 
regional studies that assessed the completion of 
chemotherapy for colorectal cancer in actual 
practice. This study aims to form a population-
based assessment for patients who were started on 
FOLFOX and FOLFIRI.  
Methods 
This retrospective cross-sectional study was 
done at Sir Paul Boffa Oncology Hospital. SPBOH 
is the only provider of systemic chemotherapy 
treatment in Malta.  It serves the whole population 
of Malta and Gozo and hosts a wide array of cancer 
patients. Permission was granted by foundation 
school audit and quality Improvement committee, 
Malta. All male patients who were started on 
FOLFOX or FOLFIRI in 2014 were included in the 
study.  Data consisting of the patient’s age, 
chemotherapy type and cycle, frequency of 
admission, tumour type and mortality were 
retrospectively extracted from the ward’s logbook, 
computer registry and ISOFT clinical manager. The 
patients’ admission dates for cycles 1, 6 and 12 
dates were documented. A full course of modified 
de Gramont FOLFOX or FOLFIRI chemotherapy 
consists of a total of 12 cycles administered every 
fortnight. All patients who were intended to 
complete 12 cycles of adjuvant or palliative 
chemotherapy were included in the analysis. 
Patients who were on neo-adjuvant treatment and 
patients on maintenance chemotherapy for more 
than 12 months were excluded. Data was analysed 
using SPSS statistical tool. We first described the 
characteristics of all study cases and then used chi-
square tests to compare the initiation and 
completion rates of adjuvant chemotherapy by 
characteristics. Multiple logistic regression was 
used to identify factors associated with the initiation 
and completion of chemotherapy.  All reported P-
values were two sided and were considered to be 
statistically significant at less than 0.05 levels. 
Results 
During 2014 SPBOH had a total of 1350 male 
admissions for chemotherapy, 874 of those 
admissions were for the infusion of either FOLFOX 
or FOLFIRI, 647 and 227 respectively.  During this 
period a total of 108 patients were newly started on 
either treatment. Only patients who were on 
FOLFOX or FOLFIRI were included. Four patients 
were excluded from the analysis because they were 
on neo-adjuvant therapy or maintenance 
chemotherapy for more than 12 cycles.  
The average age of patients was 65.2 years 
(ranging from 31-82) (64-67 95% confidence 
interval). 83% of patients were < = 70 years old. 
The main bulks, 65 patients, were between the ages 
of 60-70 years. Only 17 patients were > 70 years 
old. (Table 1, 2) (Graph 1)  
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Table 1: Age statistics Table 2: Age statistics 
Years Frequency 
Less than 65 38 
65 to 69 43 
70 to 74 9 
75 plus 11 
Total 101 
Figure 1: Age Distribution 
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88 patients were on FOLFOX and 16 on 
FOLFIRI. Of those 12 patients had upper GI 
primary malignancies, 88 had lower GI 
malignancies and only 3 had other types.  
91 patients did not receive previous 
treatments, 6 were previously treated with 
FOLFOX, 3 with FOLFIRI and 4 received other 
kinds of treatment. 89 patients (82%) did not have a 
change in Chemotherapy during the 12 cycles. 
However, the treatments of 14 patients (13%) were 
altered; 5 patients were changed to FOLFOX, 7 
changed to FOLFIRI and 3 were changed to other 
treatment regimens. 
43.8% (n=7) of patients on FOLFIRI had their 
chemotherapy changed whereas only 9.1% (n=8) of 
patients on FOLFOX had a change in treatment. 
Patients on FOLFIRI were more likely to have their 
chemotherapy changed x2 (1) = 13.176, p<0.001. 
(Table 3) 
Table 3: Chemotherapy regimen and whether or not it was changed 





Count 8 80 88 
% within Chemotherapy Regimen 9.1% 90.9% 100.0% 
FOLFIRI Count 7 9 16 
% within Chemotherapy Regimen 43.8% 56.2% 100.0% 
Total Count 15 89 104 
% within Chemotherapy Regimen 14.4% 85.6% 100.0% 
Patients on FOLFIRI were also more likely to 
have received previous treatment x2 (1) = 24.312, 
p<0.05. Only 5.7% (n=5) of patients on FOLFOX 
received previous treatment; whereas 50% (n=8) of 
patients on FOLFIRI received previous treatment. 
(Table 4) Nonetheless, no statistically significant 
correlation between the types of chemotherapy and 
whether the patient will complete his chemotherapy 
cycles were found.  
The average length of 12 cycles was 171.5 
days or 24.5 weeks. The average length of cycles 1-
6 and 6-12 were 11.6 and 12.9 weeks respectively. 
The mean difference between cycles 1-6 and cycles 
6-12 is 1.6 weeks (1-2.3 95% confidence interval).
19% (N=20) of patients had cycles longer than 7
months whereas only 10% (N=11) lasted more than
8 months on treatment.
14.5% of patients (N=15) dropped out before 
completing 6 cycles, and 27% (N=28) of patients 
before finishing the full course. Therefore only 59% 
(N=61) continued for the whole 12 cycles.  (Graph 
2) 
No statistically significant correlation was 
found between whether patients will complete 
chemotherapy and the presence of previous 
treatment, the type of chemotherapy, the presence 
of previous treatment, the primary tumour site or 
the age of the patients. 
10 patients passed away before completing 
their planned chemotherapy cycles, 8 patients had 
significant thrombotic complications like deep 
venous thrombosis, pulmonary embolism and 
arterial embolism. Most complications occurred 
before finishing 6 cycles. Treatment was 
discontinued for the rest of the patients mainly 
because of poor response to chemotherapy and 
disease progression. 
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Table 4: Chemotherapy regimen and presence of previous treatment 







Count 5 83 88 
% within 
CHEMO 
5.7% 94.3% 100.0% 
FOLFIRI 
Count 8 8 16 
% within 
CHEMO 
50.0% 50.0% 100.0% 
Total Count 13 91 104 
% within 
CHEMO 
12.5% 87.5% 100.0% 
Figure 2: Number of chemotherapy cycles 
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Discussion 
This study provides a national overview for 
the use of FOLFOX/ FOLFIRI amongst Maltese 
patients with colorectal cancer and the proportion of 
patients who complete the prescribed therapy. The 
average age for patients in our study was 65.2; we 
had a significantly lower proportion of patients 
older than 70 years than those younger. These 
findings contradict with the natural prevalence of 
the disease, as colon cancer is predominantly a 
disease of the elderly population with an expected 
increase in prevalence with age 11; nonetheless this 
may be explained by the patients and oncologists 
choice and preferences for a less aggressive 
approach to palliative care among the elderly; 
however, data were not available to statistically test 
these assumptions.   
Physicians may be reluctant to endorse such 
aggressive therapy for elderly because of the 
uncertainties regarding the risk–benefit trade-offs. 
However this is not consistent with best practice 
guidelines, as neither guideline recommends age as 
a factor to consider in treatment decisions.12 
Moreover in our study elderly patients (>75) were 
as likely to complete the course of treatment as the 
younger patients.   
The overall rate of treatment completion in 
our study was 59% (N=61). This equilibrates with 
those found in other international studies. One 
prospective study conducted in Houston Texas in 
2011 found that overall completion rate of adjuvant 
chemotherapy among patients with colon cancer 
was 62.2%. Patient’s age at diagnosis, comorbidity 
score and marital status were significantly 
associated with the rate of initiation and completion 
of adjuvant chemotherapy. 7 
Take gastro-oesophageal cancer as an 
example, a recent study found that the overall rate 
of treatment completion was 52.7% and ranged 
from 50–60% for patients with good performance 
status but was under 35% for patients aged 55 years 
or older with poor performance status. Treatment 
completion was not associated with site of cancer, 
pre-treatment stage, sex, comorbidities or histology. 
Likewise, rates of adjuvant chemotherapy in 
patients with epithelial ovarian cancer approximate 
46.5%; age and more than two comorbidities were 
identified as significant predictors.13 Our finding 
showed that no significant correlation was found 
between whether patients will complete 
chemotherapy and the presence of previous 
treatment or the primary tumour site and is 
consistent with previous research. 
FOLFOX and FOLFIRI are the most 
commonly used infusion treatments at SPBOH 
comprising of around 70% of all chemotherapies 
administered in the hospital. The average duration 
of cycles is satisfactory with around 70% finishing 
within 24 weeks. Although underrepresented in our 
study sample, patients on FOLFIRI were much 
more likely to have been given previous treatments 
and have their chemotherapy changed. Nonetheless 
both regimens had equal completion rates with no 
statistically significant difference between them.  
From our whole sample it is noted that only 16 
patients were started on FOLFIRI whereas all the 
rest were on FOLFOX. This could explain the 
higher initiation rates for FOLFOX or a likely more 
tolerable side effect profile. Nonetheless FOLFOX 
can cause significant peripheral neuropathy and 
approximately 18% of patients develop grade 3 
neuropathy.  Other quoted side effects in literature 
include cold related transient paraesthesia, allergic 
reactions, coronary artery spasm, neutopaenia, 
thyrombocytopaenia, diarrhoea and mucositis. On 
the other hand, FOLFIRI shares most of the side 
effect profiles apart from the neuropathy caused by 
Oxaliplatin. The Irinotecan part of FOLFIRI can 
cause severe diarrhoea and approximately 13% of 
patients develop grade 3-4 diarrhoea, in addition it 
may lead to asthenia and is associated with a 
cholinergic syndrome characterized by rhinitis, 
increased salivation, lacrimation, diaphoresis and 
flushing. 9-10 
A significant number in our sample did not 
complete their treatment 41% (N=43).  10 patients 
were deceased; all of those patients had evidence of 
disease progression. 15 other patients had disease 
progression with expansion of the metastatic 
deposits, this heralded the chemotherapy futile and 
patients were sent for palliative care. 8 patients 
experienced significant complications like deep 
venous thrombosis, pulmonary embolism and 
arterial embolism; however of those only two 
patients stopped chemotherapy. In the other 16 
patients the reason for discontinuation of 
chemotherapy was not clear from the data available. 
Other plausible explanations for why patients may 
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not have completed their treatment include the 
increasing financial or mobility barriers to care, 
preference changes, presence of comorbid 
conditions or mainly the debilitating 
chemotherapy-induced side effects.7
It is imperative to emphasize that systemic 
chemotherapy in metastatic colorectal cancer is 
usually not curative. However it is important to note 
that because the completion of chemotherapy is 
associated with increased survival, it is essential to 
complete the chemotherapy cycles once initiated. 
Nonetheless, in countries that do not have sufficient 
funds to administer chemotherapy, it is appropriate 
to forego chemotherapy and focus on palliative 
care. It must also be noted that, where available, a 
multidisciplinary approach and resection of 
oligometastatic disease and systemic treatment may 
cure some patients with metastatic colorectal 
cancer.7 
Clinicians and patients should consider all this 
information aided by evidence based data and the 
extensive national statistics highlighted in this study 
to base treatment decisions. Afterall by balancing 
potential benefits, the probability of treatment 
completion, toxicity of treatment, quality of life and 
overall patient preferences an informed treatment 
approach can be undertaken. 
Conclusion 
As referring physicians, we have to appreciate 
that a large proportion of referred patients for 
adjuvant or palliative chemotherapy do not proceed 
smoothly with their treatment. Many of those 
patients are middle aged fully functional 
individuals. Although chemotherapy increases 
survival in metastatic colorectal cancer, many 
patients do not complete the whole chemotherapy 
regimen due to debilitating side effects or disease 
progression. Both chemotherapies are found to be 
comparatively equivalent, however FOLFOX is 
usually preferred due to a more tolerable side effect 
profile, FOLFIRI is usually reserved as second line 
treatment, as a test for efficacy. After all, the 
physician must be confident to draw the line at the 
appropriate time and rather focus on palliative care. 
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